<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT04473352</url>
  </required_header>
  <id_info>
    <org_study_id>COVID Fluids</org_study_id>
    <nct_id>NCT04473352</nct_id>
  </id_info>
  <brief_title>COVID-19 Detection Tests in Different Body Fluids</brief_title>
  <official_title>Diagnostic Accuracy of COVID-19 Detection Tests in Different Body Fluids of Infected Men and Concordance With Viral Cultures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nucleo De Pesquisa E Desenvolvimento De Medicamentos Da Universidade Federal Do Ceara</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Universidade Federal do Ceará</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nucleo De Pesquisa E Desenvolvimento De Medicamentos Da Universidade Federal Do Ceara</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A clinical and experimental study will be carried out in which the clinician will investigate&#xD;
      the PCR of the virus early in different body fluids (blood, semen, urine, saliva) and monitor&#xD;
      its experimental clearance and evaluate in vitro diagnostic tests and inhibitory factors of&#xD;
      viral proliferation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The World Health Organization (WHO) declared Coronavirus 2019 (COVID-19) as a pandemic on&#xD;
      March 11, 2020. Due to the rapid spread of the severe acute respiratory syndrome coronavirus&#xD;
      2 virus (SARS-CoV-2), we are currently facing an unprecedented global situation. One of the&#xD;
      main pillars in the control of an epidemic is the performance of large-scale tests providing&#xD;
      a quick and accurate diagnosis so that the authorities can take timely action. Therefore,&#xD;
      tests for COVID-19 should be prompt, widely available, and implemented outside the hospital&#xD;
      environment, to avoid overloading the health system and decreasing the risks of hospital&#xD;
      transmission to other patients and health professionals. Although universal testing is a&#xD;
      cornerstone for reducing the burden of COVID-19, the accuracy of the commercially available&#xD;
      tests for COVID-19 in Brazil remains uncertain. In addition, the natural history of the&#xD;
      disease in the different organs and tissues is not unquestionably known, nor because the&#xD;
      virus develops better in some tissues and not others. There are still many unanswered&#xD;
      questions regarding COVID-19. allow more accurate knowledge of the natural history of the&#xD;
      disease in the timeline taking into account the acute and long-term phases. Several families&#xD;
      of viruses can affect the male genitourinary system, as is the case of the Zika (ZKV) and&#xD;
      Ebola viruses. There are reports that in young patients infected with ZKV, the virus persists&#xD;
      in semen for up to 6 months after the symptomatic condition. The other SARS-CoV-1 itself was&#xD;
      detected in human testicles associated with an inflammatory process (orchiepididymitis),&#xD;
      suggesting the possibility that these viruses could also be detected in the semen. As&#xD;
      SARS-CoV-1 was able to overcome the hemato-gestural barrier and induce severe testicular&#xD;
      damage in the previous outbreak, it is possible that men infected with COVID-19 may also have&#xD;
      testicular damage. Another question that remains unanswered is whether the coronavirus can&#xD;
      remain in the body of people considered recovered from Covid-19 for an indefinite period. It&#xD;
      is also unknown whether there are molecules in the body fluids capable of inhibiting viral&#xD;
      growth. The expected benefits are related to a better understanding of COVID's natural&#xD;
      history19 and which body fluids can contribute to understanding the pathophysiology of the&#xD;
      disease. It will be possible to identify the best time and the test with the best accuracy to&#xD;
      diagnose the disease. It is our intention to identify substances in body fluids with an&#xD;
      antiviral effect&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">September 2020</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Accuracy of Covid19 Detection</measure>
    <time_frame>September 2021</time_frame>
    <description>Numerical variables will be described by measurements of central tendency (mean or median) and the respective dispersion measurements. Categorical variables will be described by their absolute values, percentages, or proportions. To compare the differences of continuous variables, we will use the Student t-test or the Mann-Whitney test. For comparison of categorical data, we will use the chi-square test. Univariable and multivariable analyses will be performed to identify predictors of COVID-19 detection.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Single Group</arm_group_label>
    <description>Patients with suspected acute viral status for COVID 19 will be invited to participate in the identification of the first symptoms. The diagnosis of COVID-19 will be confirmed according to the determinations of the MS through the reaction of qRT-PCR in the nasopharynx swab. Patients will undergo multiple collections of biological material including blood, saliva, semen, and urine. Each patient will be subjected to serial sample collections. The samples will be processed and analyzed for the presence of viral RNA. Patients with 2 consecutive negative samples did not need to perform subsequent collections.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Semen, urine, and saliva: Semen samples will be obtained by the patient through masturbation,&#xD;
      and collected in sterile containers. Urine samples will be collected from the medium stream&#xD;
      at least 4 hours without emptying the bladder. Saliva samples will be obtained by the swab.&#xD;
      The first sample will be collected in the first 14 days after the onset of symptoms and the&#xD;
      others on a monthly basis. After 2 consecutive negative samples, no more samples will be&#xD;
      taken. Only the virus will be researched using qRT-PCR. Peripheral blood: Samples of&#xD;
      peripheral blood are collected through peripheral venipuncture. These samples will be&#xD;
      collected at the time of inclusion in the study to assess the viral load, and 45 days after&#xD;
      the onset of symptoms to determine the serum levels of sex hormones.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult male patients with suspected acute viral status for COVID 19 of the city of&#xD;
        Fortaleza, Ceara, Brazil, who agreed to participate in the study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects over the age of 18 years&#xD;
&#xD;
          -  Agreement with the IC&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of previous prostate surgery or vasectomy&#xD;
&#xD;
          -  Inability to assess participation in the study&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ricardo Reges, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nucleo de Pesquisa e Desenvolvimento de Medicamentos</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ricardo Reges, PhD</last_name>
    <phone>+55 85 996479789</phone>
    <email>ricardoreges@me.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eduardo P Miranda, PhD</last_name>
    <phone>+55 85 991960998</phone>
    <email>mirandaedp@gmail.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Koh D, Cunningham AC. Counting Coronavirus Disease 2019 (COVID-19) Cases: Case Definitions, Screened Populations and Testing Techniques Matter. Ann Acad Med Singap. 2020 Mar;49(3):161-165.</citation>
    <PMID>32301478</PMID>
  </reference>
  <reference>
    <citation>Lin C, Xiang J, Yan M, Li H, Huang S, Shen C. Comparison of throat swabs and sputum specimens for viral nucleic acid detection in 52 cases of novel coronavirus (SARS-Cov-2)-infected pneumonia (COVID-19). Clin Chem Lab Med. 2020 Jun 25;58(7):1089-1094. doi: 10.1515/cclm-2020-0187.</citation>
    <PMID>32301745</PMID>
  </reference>
  <reference>
    <citation>Ling Y, Xu SB, Lin YX, Tian D, Zhu ZQ, Dai FH, Wu F, Song ZG, Huang W, Chen J, Hu BJ, Wang S, Mao EQ, Zhu L, Zhang WH, Lu HZ. Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients. Chin Med J (Engl). 2020 May 5;133(9):1039-1043. doi: 10.1097/CM9.0000000000000774.</citation>
    <PMID>32118639</PMID>
  </reference>
  <reference>
    <citation>Lippi G, Simundic AM, Plebani M. Potential preanalytical and analytical vulnerabilities in the laboratory diagnosis of coronavirus disease 2019 (COVID-19). Clin Chem Lab Med. 2020 Jun 25;58(7):1070-1076. doi: 10.1515/cclm-2020-0285.</citation>
    <PMID>32172228</PMID>
  </reference>
  <reference>
    <citation>Liu R, Ma Q, Han H, Su H, Liu F, Wu K, Wang W, Zhu C. The value of urine biochemical parameters in the prediction of the severity of coronavirus disease 2019. Clin Chem Lab Med. 2020 Jun 25;58(7):1121-1124. doi: 10.1515/cclm-2020-0220.</citation>
    <PMID>32286242</PMID>
  </reference>
  <reference>
    <citation>Mardani R, Ahmadi Vasmehjani A, Zali F, Gholami A, Mousavi Nasab SD, Kaghazian H, Kaviani M, Ahmadi N. Laboratory Parameters in Detection of COVID-19 Patients with Positive RT-PCR; a Diagnostic Accuracy Study. Arch Acad Emerg Med. 2020 Apr 4;8(1):e43. eCollection 2020.</citation>
    <PMID>32259132</PMID>
  </reference>
  <reference>
    <citation>Padoan A, Cosma C, Sciacovelli L, Faggian D, Plebani M. Analytical performances of a chemiluminescence immunoassay for SARS-CoV-2 IgM/IgG and antibody kinetics. Clin Chem Lab Med. 2020 Jun 25;58(7):1081-1088. doi: 10.1515/cclm-2020-0443.</citation>
    <PMID>32301749</PMID>
  </reference>
  <reference>
    <citation>Pan F, Xiao X, Guo J, Song Y, Li H, Patel DP, Spivak AM, Alukal JP, Zhang X, Xiong C, Li PS, Hotaling JM. No evidence of severe acute respiratory syndrome-coronavirus 2 in semen of males recovering from coronavirus disease 2019. Fertil Steril. 2020 Jun;113(6):1135-1139. doi: 10.1016/j.fertnstert.2020.04.024. Epub 2020 Apr 17.</citation>
    <PMID>32482249</PMID>
  </reference>
  <reference>
    <citation>Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, Tan W. Detection of SARS-CoV-2 in Different Types of Clinical Specimens. JAMA. 2020 May 12;323(18):1843-1844. doi: 10.1001/jama.2020.3786.</citation>
    <PMID>32159775</PMID>
  </reference>
  <reference>
    <citation>Wolfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Muller MA, Niemeyer D, Jones TC, Vollmar P, Rothe C, Hoelscher M, Bleicker T, Brunink S, Schneider J, Ehmann R, Zwirglmaier K, Drosten C, Wendtner C. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020 May;581(7809):465-469. doi: 10.1038/s41586-020-2196-x. Epub 2020 Apr 1. Erratum In: Nature. 2020 Dec;588(7839):E35.</citation>
    <PMID>32235945</PMID>
  </reference>
  <reference>
    <citation>Wu J, Liu J, Li S, Peng Z, Xiao Z, Wang X, Yan R, Luo J. Detection and analysis of nucleic acid in various biological samples of COVID-19 patients. Travel Med Infect Dis. 2020 Sep-Oct;37:101673. doi: 10.1016/j.tmaid.2020.101673. Epub 2020 Apr 18.</citation>
    <PMID>32311437</PMID>
  </reference>
  <reference>
    <citation>Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020 Apr 7;323(13):1239-1242. doi: 10.1001/jama.2020.2648. No abstract available.</citation>
    <PMID>32091533</PMID>
  </reference>
  <reference>
    <citation>Yu F, Yan L, Wang N, Yang S, Wang L, Tang Y, Gao G, Wang S, Ma C, Xie R, Wang F, Tan C, Zhu L, Guo Y, Zhang F. Quantitative Detection and Viral Load Analysis of SARS-CoV-2 in Infected Patients. Clin Infect Dis. 2020 Jul 28;71(15):793-798. doi: 10.1093/cid/ciaa345.</citation>
    <PMID>32221523</PMID>
  </reference>
  <results_reference>
    <citation>Castro R, Luz PM, Wakimoto MD, Veloso VG, Grinsztejn B, Perazzo H. COVID-19: a meta-analysis of diagnostic test accuracy of commercial assays registered in Brazil. Braz J Infect Dis. 2020 Mar-Apr;24(2):180-187. doi: 10.1016/j.bjid.2020.04.003. Epub 2020 Apr 18.</citation>
    <PMID>32330437</PMID>
  </results_reference>
  <results_reference>
    <citation>Chen Y, Chen L, Deng Q, Zhang G, Wu K, Ni L, Yang Y, Liu B, Wang W, Wei C, Yang J, Ye G, Cheng Z. The presence of SARS-CoV-2 RNA in the feces of COVID-19 patients. J Med Virol. 2020 Jul;92(7):833-840. doi: 10.1002/jmv.25825. Epub 2020 Apr 25.</citation>
    <PMID>32243607</PMID>
  </results_reference>
  <results_reference>
    <citation>Infantino M, Grossi V, Lari B, Bambi R, Perri A, Manneschi M, Terenzi G, Liotti I, Ciotta G, Taddei C, Benucci M, Casprini P, Veneziani F, Fabbri S, Pompetti A, Manfredi M. Diagnostic accuracy of an automated chemiluminescent immunoassay for anti-SARS-CoV-2 IgM and IgG antibodies: an Italian experience. J Med Virol. 2020 Sep;92(9):1671-1675. doi: 10.1002/jmv.25932. Epub 2020 May 10.</citation>
    <PMID>32330291</PMID>
  </results_reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>June 18, 2020</study_first_submitted>
  <study_first_submitted_qc>July 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2020</study_first_posted>
  <last_update_submitted>August 11, 2020</last_update_submitted>
  <last_update_submitted_qc>August 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nucleo De Pesquisa E Desenvolvimento De Medicamentos Da Universidade Federal Do Ceara</investigator_affiliation>
    <investigator_full_name>Ricardo Reges Maia de Oliveira</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>Covid</keyword>
  <keyword>Body Fluids</keyword>
  <keyword>Viral Cultures</keyword>
  <keyword>Detection Tests</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT04473352
org study id: COVID Fluids
nct id: NCT04473352
lead sponsor: 
collaborator: 
has dmc: No
is fda regulated drug: No
is fda regulated device: No
A clinical and experimental study will be carried out in which the clinician will investigate
      the PCR of the virus early in different body fluids (blood, semen, urine, saliva) and monitor
      its experimental clearance and evaluate in vitro diagnostic tests and inhibitory factors of
      viral proliferation.
The World Health Organization (WHO) declared Coronavirus 2019 (COVID-19) as a pandemic on
      March 11, 2020. Due to the rapid spread of the severe acute respiratory syndrome coronavirus
      2 virus (SARS-CoV-2), we are currently facing an unprecedented global situation. One of the
      main pillars in the control of an epidemic is the performance of large-scale tests providing
      a quick and accurate diagnosis so that the authorities can take timely action. Therefore,
      tests for COVID-19 should be prompt, widely available, and implemented outside the hospital
      environment, to avoid overloading the health system and decreasing the risks of hospital
      transmission to other patients and health professionals. Although universal testing is a
      cornerstone for reducing the burden of COVID-19, the accuracy of the commercially available
      tests for COVID-19 in Brazil remains uncertain. In addition, the natural history of the
      disease in the different organs and tissues is not unquestionably known, nor because the
      virus develops better in some tissues and not others. There are still many unanswered
      questions regarding COVID-19. allow more accurate knowledge of the natural history of the
      disease in the timeline taking into account the acute and long-term phases. Several families
      of viruses can affect the male genitourinary system, as is the case of the Zika (ZKV) and
      Ebola viruses. There are reports that in young patients infected with ZKV, the virus persists
      in semen for up to 6 months after the symptomatic condition. The other SARS-CoV-1 itself was
      detected in human testicles associated with an inflammatory process (orchiepididymitis),
      suggesting the possibility that these viruses could also be detected in the semen. As
      SARS-CoV-1 was able to overcome the hemato-gestural barrier and induce severe testicular
      damage in the previous outbreak, it is possible that men infected with COVID-19 may also have
      testicular damage. Another question that remains unanswered is whether the coronavirus can
      remain in the body of people considered recovered from Covid-19 for an indefinite period. It
      is also unknown whether there are molecules in the body fluids capable of inhibiting viral
      growth. The expected benefits are related to a better understanding of COVID's natural
      history19 and which body fluids can contribute to understanding the pathophysiology of the
      disease. It will be possible to identify the best time and the test with the best accuracy to
      diagnose the disease. It is our intention to identify substances in body fluids with an
      antiviral effect
observational model: Other
time perspective: Prospective
measure: Accuracy of Covid19 Detection
time frame: September 2021
description: Numerical variables will be described by measurements of central tendency (mean or median) and the respective dispersion measurements. Categorical variables will be described by their absolute values, percentages, or proportions. To compare the differences of continuous variables, we will use the Student t-test or the Mann-Whitney test. For comparison of categorical data, we will use the chi-square test. Univariable and multivariable analyses will be performed to identify predictors of COVID-19 detection.
arm group label: Single Group
description: Patients with suspected acute viral status for COVID 19 will be invited to participate in the identification of the first symptoms. The diagnosis of COVID-19 will be confirmed according to the determinations of the MS through the reaction of qRT-PCR in the nasopharynx swab. Patients will undergo multiple collections of biological material including blood, saliva, semen, and urine. Each patient will be subjected to serial sample collections. The samples will be processed and analyzed for the presence of viral RNA. Patients with 2 consecutive negative samples did not need to perform subsequent collections.
Semen, urine, and saliva: Semen samples will be obtained by the patient through masturbation,
      and collected in sterile containers. Urine samples will be collected from the medium stream
      at least 4 hours without emptying the bladder. Saliva samples will be obtained by the swab.
      The first sample will be collected in the first 14 days after the onset of symptoms and the
      others on a monthly basis. After 2 consecutive negative samples, no more samples will be
      taken. Only the virus will be researched using qRT-PCR. Peripheral blood: Samples of
      peripheral blood are collected through peripheral venipuncture. These samples will be
      collected at the time of inclusion in the study to assess the viral load, and 45 days after
      the onset of symptoms to determine the serum levels of sex hormones.
study pop: 
sampling method: Non-Probability Sample
criteria: 
gender: Male
minimum age: 18 Years
maximum age: N/A
healthy volunteers: Accepts Healthy Volunteers
last name: Ricardo Reges, PhD
role: Principal Investigator
affiliation: Nucleo de Pesquisa e Desenvolvimento de Medicamentos
last name: Ricardo Reges, PhD
phone: +55 85 996479789
email: ricardoreges@me.com
last name: Eduardo P Miranda, PhD
phone: +55 85 991960998
email: mirandaedp@gmail.com
citation: Koh D, Cunningham AC. Counting Coronavirus Disease 2019 (COVID-19) Cases: Case Definitions, Screened Populations and Testing Techniques Matter. Ann Acad Med Singap. 2020 Mar;49(3):161-165.
PMID: 32301478
citation: Lin C, Xiang J, Yan M, Li H, Huang S, Shen C. Comparison of throat swabs and sputum specimens for viral nucleic acid detection in 52 cases of novel coronavirus (SARS-Cov-2)-infected pneumonia (COVID-19). Clin Chem Lab Med. 2020 Jun 25;58(7):1089-1094. doi: 10.1515/cclm-2020-0187.
PMID: 32301745
citation: Ling Y, Xu SB, Lin YX, Tian D, Zhu ZQ, Dai FH, Wu F, Song ZG, Huang W, Chen J, Hu BJ, Wang S, Mao EQ, Zhu L, Zhang WH, Lu HZ. Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients. Chin Med J (Engl). 2020 May 5;133(9):1039-1043. doi: 10.1097/CM9.0000000000000774.
PMID: 32118639
citation: Lippi G, Simundic AM, Plebani M. Potential preanalytical and analytical vulnerabilities in the laboratory diagnosis of coronavirus disease 2019 (COVID-19). Clin Chem Lab Med. 2020 Jun 25;58(7):1070-1076. doi: 10.1515/cclm-2020-0285.
PMID: 32172228
citation: Liu R, Ma Q, Han H, Su H, Liu F, Wu K, Wang W, Zhu C. The value of urine biochemical parameters in the prediction of the severity of coronavirus disease 2019. Clin Chem Lab Med. 2020 Jun 25;58(7):1121-1124. doi: 10.1515/cclm-2020-0220.
PMID: 32286242
citation: Mardani R, Ahmadi Vasmehjani A, Zali F, Gholami A, Mousavi Nasab SD, Kaghazian H, Kaviani M, Ahmadi N. Laboratory Parameters in Detection of COVID-19 Patients with Positive RT-PCR; a Diagnostic Accuracy Study. Arch Acad Emerg Med. 2020 Apr 4;8(1):e43. eCollection 2020.
PMID: 32259132
citation: Padoan A, Cosma C, Sciacovelli L, Faggian D, Plebani M. Analytical performances of a chemiluminescence immunoassay for SARS-CoV-2 IgM/IgG and antibody kinetics. Clin Chem Lab Med. 2020 Jun 25;58(7):1081-1088. doi: 10.1515/cclm-2020-0443.
PMID: 32301749
citation: Pan F, Xiao X, Guo J, Song Y, Li H, Patel DP, Spivak AM, Alukal JP, Zhang X, Xiong C, Li PS, Hotaling JM. No evidence of severe acute respiratory syndrome-coronavirus 2 in semen of males recovering from coronavirus disease 2019. Fertil Steril. 2020 Jun;113(6):1135-1139. doi: 10.1016/j.fertnstert.2020.04.024. Epub 2020 Apr 17.
PMID: 32482249
citation: Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, Tan W. Detection of SARS-CoV-2 in Different Types of Clinical Specimens. JAMA. 2020 May 12;323(18):1843-1844. doi: 10.1001/jama.2020.3786.
PMID: 32159775
citation: Wolfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Muller MA, Niemeyer D, Jones TC, Vollmar P, Rothe C, Hoelscher M, Bleicker T, Brunink S, Schneider J, Ehmann R, Zwirglmaier K, Drosten C, Wendtner C. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020 May;581(7809):465-469. doi: 10.1038/s41586-020-2196-x. Epub 2020 Apr 1. Erratum In: Nature. 2020 Dec;588(7839):E35.
PMID: 32235945
citation: Wu J, Liu J, Li S, Peng Z, Xiao Z, Wang X, Yan R, Luo J. Detection and analysis of nucleic acid in various biological samples of COVID-19 patients. Travel Med Infect Dis. 2020 Sep-Oct;37:101673. doi: 10.1016/j.tmaid.2020.101673. Epub 2020 Apr 18.
PMID: 32311437
citation: Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020 Apr 7;323(13):1239-1242. doi: 10.1001/jama.2020.2648. No abstract available.
PMID: 32091533
citation: Yu F, Yan L, Wang N, Yang S, Wang L, Tang Y, Gao G, Wang S, Ma C, Xie R, Wang F, Tan C, Zhu L, Guo Y, Zhang F. Quantitative Detection and Viral Load Analysis of SARS-CoV-2 in Infected Patients. Clin Infect Dis. 2020 Jul 28;71(15):793-798. doi: 10.1093/cid/ciaa345.
PMID: 32221523
citation: Castro R, Luz PM, Wakimoto MD, Veloso VG, Grinsztejn B, Perazzo H. COVID-19: a meta-analysis of diagnostic test accuracy of commercial assays registered in Brazil. Braz J Infect Dis. 2020 Mar-Apr;24(2):180-187. doi: 10.1016/j.bjid.2020.04.003. Epub 2020 Apr 18.
PMID: 32330437
citation: Chen Y, Chen L, Deng Q, Zhang G, Wu K, Ni L, Yang Y, Liu B, Wang W, Wei C, Yang J, Ye G, Cheng Z. The presence of SARS-CoV-2 RNA in the feces of COVID-19 patients. J Med Virol. 2020 Jul;92(7):833-840. doi: 10.1002/jmv.25825. Epub 2020 Apr 25.
PMID: 32243607
citation: Infantino M, Grossi V, Lari B, Bambi R, Perri A, Manneschi M, Terenzi G, Liotti I, Ciotta G, Taddei C, Benucci M, Casprini P, Veneziani F, Fabbri S, Pompetti A, Manfredi M. Diagnostic accuracy of an automated chemiluminescent immunoassay for anti-SARS-CoV-2 IgM and IgG antibodies: an Italian experience. J Med Virol. 2020 Sep;92(9):1671-1675. doi: 10.1002/jmv.25932. Epub 2020 May 10.
PMID: 32330291
responsible party type: Principal Investigator
investigator affiliation: Nucleo De Pesquisa E Desenvolvimento De Medicamentos Da Universidade Federal Do Ceara
investigator full name: Ricardo Reges Maia de Oliveira
investigator title: PhD
mesh term: COVID-19
sharing ipd: No